卡瑞利珠单抗注射液临床用药特征分析

Abstract
Figure/Table
References
Related Citation (14)

Download: PDF (983 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To probe the medication characteristics of Camrelizumab injection in the real world. Methods The data information of patients treated with carrilizumab in “HIS” database of the 960th Hospital of Chinese PLA from January 2018 to April 2022 were retrieved, and the basic characteristics of patients were statistically described. The Apriori model algorithm was used to analyze the drugs, pharmacology and function of carrilizumab to clarify the combination of carrilizumab injection in real world. Results Among the 306 patients who used Karelizumab, the average age was (64.69±9.62) years, and the male-female ratio was about 3.31∶1. The use of Karelizumab increased year by year, among which the top three were lung malignant tumor (39.93%), esophageal malignant tumor (28.58%) and gastric malignant tumor (12.34%). Karelizumab was used in combination with anti-tumor drugs and digestive system drugs (the support rate was 52.87%), among which anti-emetic drugs were the main digestive drugs. Among the drugs, nedaplatin+paclitaxel (elevation 2.41) and dexamethasone+ondansetron hydrochloride (elevation 1.73) had high correlation. Chinese patent medicines were mainly anti-malignant tumor agents, dampness-eliminating agents and tonic formulae. Eighty-four cases (242 times, accounting for 21.96%) of irrational drug use were mainly gastric cancer, pancreatic cancer and intestinal cancer. Conclusions As a new domestic anti-tumor immune drug, Karelizumab has attracted more and more attention from physicians and patients, and more attention should be paid to its extra-indication use and collection and treatment of adverse reactions.

Key words： Camrelizumab the real world hospital information system characteristics of combined medication

Received: 18 September 2022

R979.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SUN Yanshun
	JIANG Shiyao
	YANG Dong
	CUI Yu
	LIU Qing
	YU Lili

Cite this article:

SUN Yanshun,JIANG Shiyao,YANG Dong等. Analysis of medication characteristics of Camrelizumab injection in the real world[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2023, 34(4): 325-329.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2023/V34/I4/325

[1]	邢续扬,王孝春,何伟.肿瘤免疫治疗及其药物研发进展[J].中国药科大学学报,2021,52(1):10-19.
[2]	Ai L, Chen J, Yan H, et al. Research status and outlook of PD-1/PD-L1 inhibitors for cancer therapy[J]. Drug Des Devel Ther, 2020,14:3625-3649.
[3]	全球肿瘤医生网. 2021年中国国内上市的癌症肿瘤免疫治疗(PD-1/PD-L1)药物有哪些？[EB/OL].[2022-05-01]. http://www.globecancer.com/azzx/show.php?itemid=14695.
[4]	孙铮,李勇.卡瑞利珠单抗联合化疗对比化疗在晚期鳞状非小细胞肺癌一线治疗中的成本效果分析[J].中国医院药学杂志,2022,42(20):2148-2152.
[5]	周虹,林燕芳,蔡莉莉,等.卡瑞利珠单抗临床应用评价和安全性分析[J].中国现代应用药学,2022,39(14):1880-1886.
[6]	王征,侯维,郑素军.卡瑞利珠单抗治疗原发性肝癌致肌炎及横纹肌溶解综合征一例报告[J].北京医学,2021,43(9):941-942.
[7]	World Health Organization. International statistical classification of diseases and health-related problems(10th revision) [M]//DONG JW.2nd ed. Beijing: People’s Medical Publishing House, 2008.
[8]	Chen W B, Pan X L. Diagnostics [M]. 7th ed. Beijing: People’s Medical Publishing House, 2008.
[9]	国家药典委员会.中华人民共和国药典:一部[M].北京:中国医药科技出版社,2020.
[10]	马越,朱圣文,孙蕾,等.我国已上市PD-1/PD-L1抑制剂经济性评价的系统分析[J].中国药房,2021,32(15):1885-1893.
[11]	董菊红,宗云岗,张标,等. 国内PD-1抑制剂研发与上市竞争透析[J]. 中国处方药,2022,20(3):28-31.
[12]	刘宗超,李哲轩,张阳,等.2020全球癌症统计报告解读[J].肿瘤综合治疗电子杂志,2021,7(2):1-13.
[13]	刘俊,严婷,刘红,等.2013～2019年广州某院消化系统恶性肿瘤流行病学分析[J].医学信息,2020,33(23):137-140.
[14]	丁政,杨利军,刘冬,等.重庆市南川区8530例恶性肿瘤流行病学特征分析[J].重庆医学,2019,48(23):4102-4104, 4107.
[15]	孟新源,梁永红,阿提合尼木·艾买提,等.2000张门诊抗肿瘤药处方超药品说明书用药情况分析[J].中国医院用药评价与分析,2022,22(6):758-760,764.
[16]	房立源,李慧杰,王志鹏,等.基于数据挖掘和网络药理学探讨中药治疗化疗相关性恶心呕吐的用药规律和机制[J].湖南中医杂志,2022,38(8):29-35.
[17]	庞英,唐丽丽.癌症患者化疗相关的预期性恶心呕吐(综述)[J].中国心理卫生杂志, 2017, 31(7):505-510.
[18]	Chinese Society of Clinical Oncology. Guidelines for the prevention and treatment of nausea and vomiting related to antitumor therapy 2019 Edition [M]. Beijing: People’s Health Publishing House, 2019.
[19]	Kim H J, Shin S W, Song E K, et al. Ramosetron versus ondansetron in combination with aprepitant and dexamethasone for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: a multicenter, randomized phase III trial, KCSG PC10-21[J]. Oncologist, 2015, 20(12): 1440-1447.